New Delhi: In response to the GSK's revised Phase IV clinical trial protocol for the pulmonary fixed dose combination (FDC) drug, Fluticasone Furoate100mg, Umeclidnium Bromide 62.5mg,Vilanterol Trifenatate 25mg powder for inhalation, the Subject Export Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has recommended the firm to amend the Phase IV...
New Delhi: In response to the GSK's revised Phase IV clinical trial protocol for the pulmonary fixed dose combination (FDC) drug, Fluticasone Furoate100mg, Umeclidnium Bromide 62.5mg,Vilanterol Trifenatate 25mg powder for inhalation, the Subject Export Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has recommended the firm to amend the Phase IV clinical trial protocol.
This came after the drug major GSK presented the revised Phase IV clinical trial protocol of the pulmonary FDC drug Fluticasone Furoate100mg plus Umeclidnium Bromide62.5mg plus
Vilanterol Trifenatate 25mg powder for inhalation before the committee.
The combination of fluticasone furoate, umeclidinium bromide, and
vilanterol trifenatate is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary (COPD; a group of diseases that affect the lungs and airways, that includes chronic bronchitis and emphysema). It is also used in adults to control wheezing, shortness of breath, coughing, and chest tightness caused by asthma.
Fluticasone furoate is an inhaled corticosteroid that can be used as maintenance treatment of asthma and/or chronic obstructive pulmonary disease (COPD) depending on the product. Fluticasone furoate works through an unknown mechanism to affect the action of various cell types and mediators of inflammation but Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes.
Umeclidinium Bromide is the bromide salt form of umeclidinium, a muscarinic receptor antagonist, with bronchodilator activity.It works by blocking some receptors called muscarinic receptors, which control the contraction of muscles. When umeclidinium bromide is inhaled, it relaxes the muscles of the airways.
Vilanterol is in a class of medications called long-acting beta-agonists (LABAs).Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP).
The combination of fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate works by relaxing and opening air passages in the lungs, making it easier to breathe.
At the recent SEC meeting for Pulmonary held on 7th December 2022, the expert panel extensively reviewed the revised Phase IV clinical trail protocol of the pulmonary FDC drug Fluticasone Furoate100mg plus Umeclidnium Bromide62.5mg plus Vilanterol Trifenatate 25mg powder for inhalation presented by the drug major Glaxosmithkline Pharma.
After detailed deliberation, the committee recommended the amendment in the revised Phase IV clinical trial study protocol.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd